RUSTI HAUGE: Open Payments
NPI 1639124092 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$354 in 15 payments from 10 companies in 2025. Trend: 2023 $421 · 2024 $518 · 2025 $354
Food & beverage: $354
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 3 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| ABBVIE INC. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $31 |
| E.R. Squibb & Sons, L.L.C. | 1 | $27 |
| Alkermes, Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Janssen Pharmaceuticals, Inc | 1 | $15 |
Products named: INGREZZA, TRINTELLIX, VRAYLAR, CAPLYTA, REXULTI, COBENFY, ARISTADA, Auvelity.
Industry payments across TX — which companies pay providers there.
